Enanta Pharmaceuticals (ENTA) Competitors $7.11 -0.47 (-6.20%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$7.11 0.00 (0.00%) As of 08/1/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ENTA vs. SEPN, ABUS, EOLS, ZVRA, BCYC, KROS, TYRA, RAPP, ARVN, and TSHAShould you be buying Enanta Pharmaceuticals stock or one of its competitors? The main competitors of Enanta Pharmaceuticals include Septerna (SEPN), Arbutus Biopharma (ABUS), Evolus (EOLS), Zevra Therapeutics (ZVRA), Bicycle Therapeutics (BCYC), Keros Therapeutics (KROS), Tyra Biosciences (TYRA), Rapport Therapeutics (RAPP), Arvinas (ARVN), and Taysha Gene Therapies (TSHA). These companies are all part of the "pharmaceutical products" industry. Enanta Pharmaceuticals vs. Its Competitors Septerna Arbutus Biopharma Evolus Zevra Therapeutics Bicycle Therapeutics Keros Therapeutics Tyra Biosciences Rapport Therapeutics Arvinas Taysha Gene Therapies Septerna (NASDAQ:SEPN) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership. Do analysts prefer SEPN or ENTA? Septerna presently has a consensus target price of $26.75, indicating a potential upside of 119.08%. Enanta Pharmaceuticals has a consensus target price of $18.50, indicating a potential upside of 160.20%. Given Enanta Pharmaceuticals' higher possible upside, analysts clearly believe Enanta Pharmaceuticals is more favorable than Septerna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Septerna 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Enanta Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Is SEPN or ENTA more profitable? Septerna has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -149.57%. Septerna's return on equity of 0.00% beat Enanta Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets SepternaN/A N/A N/A Enanta Pharmaceuticals -149.57%-79.83%-26.65% Which has higher valuation & earnings, SEPN or ENTA? Septerna has higher earnings, but lower revenue than Enanta Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSepterna$1.08M503.78-$71.80MN/AN/AEnanta Pharmaceuticals$67.64M2.25-$116.04M-$4.54-1.57 Does the media refer more to SEPN or ENTA? In the previous week, Enanta Pharmaceuticals had 8 more articles in the media than Septerna. MarketBeat recorded 9 mentions for Enanta Pharmaceuticals and 1 mentions for Septerna. Enanta Pharmaceuticals' average media sentiment score of 0.69 beat Septerna's score of 0.00 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enanta Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in SEPN or ENTA? 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 4.3% of Septerna shares are held by insiders. Comparatively, 13.9% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryEnanta Pharmaceuticals beats Septerna on 7 of the 13 factors compared between the two stocks. Get Enanta Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTA vs. The Competition Export to ExcelMetricEnanta PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$162.03M$2.46B$5.49B$9.52BDividend YieldN/A1.81%4.73%4.09%P/E Ratio-1.578.9728.7523.81Price / Sales2.25437.65372.2066.02Price / CashN/A157.7635.4557.96Price / Book1.174.838.275.55Net Income-$116.04M$31.62M$3.25B$259.20M7 Day Performance-3.92%-5.28%-3.72%-4.64%1 Month Performance-10.79%4.38%4.30%4.41%1 Year Performance-48.85%-2.49%25.87%17.95% Enanta Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTAEnanta Pharmaceuticals3.7048 of 5 stars$7.11-6.2%$18.50+160.2%-52.0%$162.03M$67.64M-1.57160News CoverageUpcoming EarningsAnalyst RevisionGap DownSEPNSepterna1.3689 of 5 stars$13.83-0.4%$26.75+93.4%N/A$618.47M$1.08M0.00N/AABUSArbutus Biopharma2.1834 of 5 stars$3.35+4.0%$5.50+64.2%-14.2%$616.72M$6.17M-8.1790News CoverageUpcoming EarningsEOLSEvolus3.5649 of 5 stars$9.28-2.6%$23.75+155.9%-34.8%$614.45M$266.27M-10.43170News CoverageUpcoming EarningsZVRAZevra Therapeutics2.0711 of 5 stars$10.81-3.7%$23.71+119.4%+76.3%$614.05M$23.61M-5.6920Trending NewsShort Interest ↑Analyst RevisionBCYCBicycle Therapeutics3.4273 of 5 stars$8.61-1.0%$24.22+181.3%-67.2%$602.51M$35.28M-2.74240Upcoming EarningsGap DownKROSKeros Therapeutics2.5945 of 5 stars$14.51+0.3%$30.56+110.6%-71.6%$587.29M$214.71M-80.61100News CoveragePositive NewsUpcoming EarningsTYRATyra Biosciences1.6645 of 5 stars$11.11+0.5%$30.83+177.5%-51.8%$587.17MN/A-6.8220News CoverageUpcoming EarningsShort Interest ↑RAPPRapport Therapeutics1.2157 of 5 stars$16.74+4.3%$28.00+67.3%-31.0%$585.79MN/A-4.85N/AARVNArvinas3.4814 of 5 stars$7.61-2.9%$20.29+166.6%-72.3%$572.25M$263.40M-11.53420News CoverageUpcoming EarningsTSHATaysha Gene Therapies2.9438 of 5 stars$2.67+0.8%$8.17+205.9%+21.8%$568.85M$7.22M-7.85180News CoveragePositive NewsShort Interest ↑ Related Companies and Tools Related Companies SEPN Competitors ABUS Competitors EOLS Competitors ZVRA Competitors BCYC Competitors KROS Competitors TYRA Competitors RAPP Competitors ARVN Competitors TSHA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENTA) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enanta Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
